Mostrar el registro sencillo del ítem

dc.contributor.authorMartínez Rubio, Álvaro 
dc.contributor.authorChulián, Salvador
dc.contributor.authorBlázquez Goñi, Cristina
dc.contributor.authorRamírez-Orellana, Manuel
dc.contributor.authorPérez Martínez, Antonio
dc.contributor.authorNavarro Zapata, Alfonso
dc.contributor.authorFerreras, Cristina
dc.contributor.authorPérez-García, Víctor M.
dc.contributor.authorRosa Durán, María 
dc.contributor.otherMatemáticases_ES
dc.date.accessioned2021-09-20T10:45:30Z
dc.date.available2021-09-20T10:45:30Z
dc.date.issued2021-06
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/10498/25459
dc.description.abstractChimeric Antigen Receptor (CAR) T-cell therapy has demonstrated high rates of response in recurrent B-cell Acute Lymphoblastic Leukemia in children and young adults. Despite this success, a fraction of patients' experience relapse after treatment. Relapse is often preceded by recovery of healthy B cells, which suggests loss or dysfunction of CAR T-cells in bone marrow. This site is harder to access, and thus is not monitored as frequently as peripheral blood. Understanding the interplay between B cells, leukemic cells, and CAR T-cells in bone marrow is paramount in ascertaining the causes of lack of response. In this paper, we put forward a mathematical model representing the interaction between constantly renewing B cells, CAR T-cells, and leukemic cells in the bone marrow. Our model accounts for the maturation dynamics of B cells and incorporates effector and memory CAR T-cells. The model provides a plausible description of the dynamics of the various cellular compartments in bone marrow after CAR T infusion. After exploration of the parameter space, we found that the dynamics of CAR T product and disease were independent of the dose injected, initial B-cell load, and leukemia burden. We also show theoretically the importance of CAR T product attributes in determining therapy outcome, and have studied a variety of possible response scenarios, including second dosage schemes. We conclude by setting out ideas for the refinement of the model.es_ES
dc.description.sponsorshipThis work was partially supported by the Fundacion Espanola para la Ciencia y la Tecnologia (UCA PR214), the Asociacion Pablo Ugarte (APU, Spain), Junta de Comunidades de Castilla-La Mancha (SBPLY/17/180501/000154), Ministry of Science and Technology, Spain (PID2019110895RB-I00), and Inversion Territorial Integrada de la Provincia de Cadiz (ITI-0038-2019).es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceInt. J. Mol. Sci. 2021, 22(12), 6371es_ES
dc.subjectCAR Tes_ES
dc.subjectmathematical modeles_ES
dc.subjectacute lymphoblastic leukemiaes_ES
dc.subjectB celles_ES
dc.subjectbone marrowes_ES
dc.titleA Mathematical Description of the Bone Marrow Dynamics during CAR T-Cell Therapy in B-Cell Childhood Acute Lymphoblastic Leukemiaes_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/ijms22126371
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2019-110895RB-I00/ES/MODELOS MATEMATICOS EN ONCOLOGIA/es_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional